Thus, PTPN22 overexpression may serve to selectively uncouple AKT from downstream proapoptotic BCR pathways and thus protect CLL cells from tolerance mechanisms that eliminate autoreactive B cells. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.